Dr. Raoof’s interest in reducing the burden of tobacco-related diseases led her to the MD-PhD program at Harvard-MIT (HST), where she studied the epigenetic basis of drug tolerance in oncogene-mutant lung cancers and designed drug combinations to block the evolution of resistance. Her concurrent work in the anti-tobacco space shifted her post-graduate scientific interests from drug development for late-stage cancers to early detection and prevention of cancer. She is currently a Radiation Oncology Resident at Memorial Sloan Kettering Cancer Center.